PRME
Prime Medicine, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
3.45
▲ 0.21 (6.48%)
MARKET · —
Price
Open
3.30
Prev close
3.24
Day high
3.48
Day low
3.24
Volume
3.58M
Market cap
$614.87M
P/E (TTM)
—
52W range
2.67 – 6.94
Trailing performance
Returnvs SPY
1W
+9.71%
+11.1%
1M
+14.14%
+10.4%
3M
+14.92%
+11.8%
6M
+3.67%
-7.4%
YTD
-2.31%
-14.6%
1Y
+4.63%
-15.4%
3Y
-70.85%
-145.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$614.87M
Enterprise value$620.50M
Revenue (TTM)$4.07M
Gross profit$-142.13M
EBITDA$-189.12M
Net income$-187.89M
EPS (TTM)$-1.05
Free cash flow$-75.78M
Total cash$95.07M
Total debt$112.48M
Book value / share$0.23
Shares outstanding181.38M
Float112.25M
Short % of float24.67%
Dividend yield—
Beta (5Y)2.31
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.83
PEG ratio—
Price / sales—
Price / book15.07
EV / revenue152.35
EV / EBITDA-3.28
Gross margin0.00%
Operating margin-3750.87%
Profit margin0.00%
Return on equity-373.29%
Return on assets-46.52%
Debt / equity282.54
Current ratio3.06
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $4.63M | $2.98M | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$201.14M | -$195.88M | -$198.13M | -$142.01M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$201.14M | -$195.88M | -$198.13M | -$142.01M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.26 | -0.24 | +6.0% |
| Mar 2026 | -0.25 | -0.28 | -12.6% |
| Dec 2025 | -0.26 | -0.24 | +6.9% |
| Sep 2025 | -0.25 | -0.32 | -29.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.23 | 12 | $2.47M | +101.7% |
| Next quarter | -0.20 | 12 | $8.70M | +937.7% |
| Current year | -0.94 | 14 | $12.13M | +161.9% |
| Next year | -0.88 | 12 | $13.80M | +13.8% |
Analyst targets & ownership
Mean target$7.30
High target$11.00
Low target$4.25
Implied upside111.46%
Analyst count11
ConsensusBUY
Strong buy / Buy1 / 9
Hold3
Sell / Strong sell0 / 0
Held by insiders23.66%
Held by institutions71.11%
Institutions holding258
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
42.10M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 1, 25 | NELSEN ROBERT TAYLOR Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 3.03M | $10.00M | Indirect |
| Aug 1, 25 | ARCH VENTURE PARTNERS X LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 3.03M | $10.00M | Indirect |
| Aug 1, 25 | GV 2021 GP, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.50M | $4.95M | Indirect |
| Jun 30, 25 | LIU DAVID R Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.00K | $52.83K | Direct |
| Jun 23, 25 | LIU DAVID R Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.00K | $45.40K | Direct |
| Jun 16, 25 | LIU DAVID R Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.00K | $31.20K | Direct |
| Jun 11, 25 | LIU DAVID R Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.00K | $33.59K | Direct |
| May 21, 25 | REINE ALLAN Chief Executive Officer |
BUY | 125.00K | $147.15K | Direct |
| May 21, 25 | LEE ANN LOUISE Officer |
BUY | 100.00K | $113.00K | Direct |
| May 20, 25 | BRUDNICK RICHARD Officer |
BUY | 20.00K | $23.79K | Direct |
| Oct 8, 24 | GOTTESDIENER KEITH MICHAEL Chief Executive Officer |
STOCK | 226.93K | $0 | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ARCH VENTURE PARTNERS X LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
BRUDNICK RICHARD |
Officer | 20.00K | Purchase |
GOTTESDIENER KEITH MICHAEL |
Chief Executive Officer | — | Stock Gift |
GV 2021 GP, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
LEE ANN LOUISE |
Officer | 100.00K | Purchase |
LIU DAVID R |
Beneficial Owner of more than 10% of a Class of Security | 20.24M | Purchase |
NELSEN ROBERT TAYLOR |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
REINE ALLAN |
Chief Executive Officer | 125.00K | Purchase |
Moving averages & technicals
SMA 10
3.23
+6.94% from price
SMA 20
3.11
+8.95% from price
SMA 50
3.28
+3.28% from price
SMA 100
3.32
+3.92% from price
SMA 200
3.56
-4.67% from price
EMA 12
3.22
+7.20% from price
EMA 26
3.20
+7.68% from price
EMA 50
3.24
+6.35% from price
RSI (14)
54.9
Neutral
MACD (12,26,9)
0.01
Hist 0.05
ATR (14)
0.23
6.76% of price
Realised vol 30D
73.7%
Annualised
Bollinger upper
3.43
20, 2σ
Bollinger lower
2.79
20, 2σ
50 / 200 cross
Death
3.28 vs 3.56
Trend bias
Below 200
-4.67%
Risk profile
Beta vs SPY
2.30
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
73.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-59.5%
Peak to trough
Max drawdown 5Y
-94.6%
Peak to trough
ATR 14
0.23
6.76% of price
Beta (reported)
2.31
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.09
Call-heavy session
Put / call open interest
0.35
Positioning, not flow
Max pain
3.00
-11.5% from spot
ATM implied vol
90.6%
Nearest strike to spot
Skew (10% OTM)
-14.5%
Calls bid over puts
Call volume
182
Contracts, this expiry
Put volume
16
Contracts, this expiry
Heaviest call OI
4.00
174 contracts
Heaviest put OI
3.00
122 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 16d ago
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · 16d ago
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
Barrons.com · 23d ago
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Zacks · 23d ago
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
GlobeNewswire · 30d ago
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)
Insider Monkey · 38d ago
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
Insider Monkey · 39d ago
Cathie Wood Dumps AMD, Doubles Down on Meta Stock
GuruFocus.com · 43d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.